Euroopan unioni - suomi - EMA (European Medicines Agency)

incyte biosciences distribution b.v. - ponatinib - leukemia, myeloid; leukemia, lymphoid - antineoplastic agents, protein kinase inhibitors - iclusig is indicated in adult patients withchronic phase, accelerated phase, or blast phase chronic myeloid leukaemia (cml) who are resistant to dasatinib or nilotinib; who are intolerant to dasatinib or nilotinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the t315i mutationphiladelphia chromosome positive acute lymphoblastic leukaemia (ph+ all) who are resistant to dasatinib; who are intolerant to dasatinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the t315i mutation. katso kohdat 4. 2 assessment of cardiovascular status prior to start of therapy and 4. 4 situations where an alternative treatment may be considered.

Euroopan unioni - suomi - EMA (European Medicines Agency)

novartis europharm limited - crizanlizumab - anemia, sickle cell - other hematological agents - adakveo is indicated for the prevention of recurrent vaso occlusive crises (vocs) in sickle cell disease patients aged 16 years and older. it can be given as an add on therapy to hydroxyurea/hydroxycarbamide (hu/hc) or as monotherapy in patients for whom hu/hc is inappropriate or inadequate.

Euroopan unioni - suomi - EMA (European Medicines Agency)

novartis europharm limited - indacaterol, glycopyrronium bromide, mometasone - astma - obstruktiivisten hengitystiesairauksien lääkkeet, - enerzair breezhaler is indicated as a maintenance treatment of asthma in adult patients not adequately controlled with a maintenance combination of a long acting beta2 agonist and a high dose of an inhaled corticosteroid who experienced one or more asthma exacerbations in the previous year.

Euroopan unioni - suomi - EMA (European Medicines Agency)

novartis europharm limited - glycopyrronium bromide, indacaterol (acetate), mometasone furoate - astma - obstruktiivisten hengitystiesairauksien lääkkeet, - maintenance treatment of asthma in adults whose disease is not adequately controlled.

Euroopan unioni - suomi - EMA (European Medicines Agency)

novartis europharm limited  - capmatinib dihydrochloride monohydrate - karsinooma, ei-pienisoluinen keuhko - antineoplastiset aineet - tabrecta as monotherapy is indicated for the treatment of adult patients with advanced non small cell lung cancer (nsclc) harbouring alterations leading to mesenchymal epithelial transition factor gene exon 14 (metex14) skipping, who require systemic therapy following prior treatment with immunotherapy and/or platinum based chemotherapy.

Euroopan unioni - suomi - EMA (European Medicines Agency)

novartis europharm limited  - lutetium (177lu) vipivotide tetraxetan - eturauhasen kasvaimet, kastraatio-resistentin - terapeuttiset radiofarmaseuttiset valmisteet - pluvicto in combination with androgen deprivation therapy (adt) with or without androgen receptor (ar) pathway inhibition is indicated for the treatment of adult patients with progressive prostate-specific membrane antigen (psma)-positive metastatic castration-resistant prostate cancer (mcrpc) who have been treated with ar pathway inhibition and taxane based chemotherapy.

Euroopan unioni - suomi - EMA (European Medicines Agency)

janssen-cilag international n.v. - telaprevir - hepatiitti c, krooninen - antiviraalit systeemiseen käyttöön - incivo, yhdessä peginterferoni alfan ja ribaviriinin kanssa on tarkoitettu hoitoon genotyyppi-1 krooninen hepatiitti c aikuiset potilaat, joilla on kompensoitunut maksasairaus (mukaan lukien maksakirroosi):jotka ovat aiemmin hoitamattomilla, jotka on aiemmin hoidettu interferoni alfan (pegyloidun tai pegyloimattoman) yksinään tai yhdistelmänä ribaviriinin kanssa, myös relapsers, osittainen hoitovaste ja null vaste.

Euroopan unioni - suomi - EMA (European Medicines Agency)

novartis europharm ltd - aliskireenia, amlodipiinia - verenpainetauti - reniini-angiotensiinijärjestelmään vaikuttavat aineet - rasilamlo on tarkoitettu välttämättömän hypertension hoitoon aikuispotilailla, joiden verenpainetta ei ole riittävästi hallinnassa aliskireenin tai amlodipiinin käytön kanssa yksinään.

Euroopan unioni - suomi - EMA (European Medicines Agency)

novartis europharm ltd. - aliskireenia, amlodipiinia, hydrochlorothiazide - verenpainetauti - sydän- ja verisuonijärjestelmä - rasitrio on tarkoitettu kohtelu essentiaalinen hypertensio kuin korvaushoito aikuisilla, joiden verenpaine on asianmukaisesti hallinnassa aliskiren, amlodipine ja hydrochlorothiazide annetaan samanaikaisesti samalla annoksella yhdistelmä tasolla kuin yhdistelmä.

Euroopan unioni - suomi - EMA (European Medicines Agency)

novartis europharm ltd. - aliskireeni - verenpainetauti - reniini-angiotensiinijärjestelmään vaikuttavat aineet - essentiaalisen hypertension hoito.